RecallRadar

FDA Drug recall D-0065-2023

PF-Neostigmine Methylsulfate Injection, USP 3 mg/3 mL (1 mg/mL) vial, Rx Only, Nephron 503B Outsourcing Facility 4500 12th Street Extension…

On 2022-11-23 the FDA classified a Class II recall of PF-Neostigmine Methylsulfate Injection, USP 3 mg/3 mL (1 mg/mL) vial, Rx Only, Nephron 503B Outsourcing Facility 4500 12th Street Extension… by Nephron Sterile Compounding Center, citing CGMP Deviations: Potential for cross contamination due to product carry over.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0065-2023
ClassificationClass II
Statusterminated
Initiated2022-11-10
Published2022-11-23
Last updated2026-09-13 11:52 UTC
CompanyNephron Sterile Compounding Center
DistributionUS

Product

PF-Neostigmine Methylsulfate Injection, USP 3 mg/3 mL (1 mg/mL) vial, Rx Only, Nephron 503B Outsourcing Facility 4500 12th Street Extension West Columbia, SC 29172, NDC 69374-932-33, UPC 3 69374-93233 2.

Reason

CGMP Deviations: Potential for cross contamination due to product carry over.

Identifiers

upc369374932332
code_infoLots: NE1062A, NE1062B Exp. 12/02/2022; NE1065A, NE1065B Exp. 12/13/2022; NE2011A, NE2011B Exp. 03/15/2022.

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0065-2023%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.